Latest news with #Telliez
Business Insider
19-07-2025
- Business
- Business Insider
Kepler Capital Sticks to Its Buy Rating for Galderma Group AG (GALD)
In a report released on July 17, Justine Telliez from Kepler Capital maintained a Buy rating on Galderma Group AG, with a price target of CHF137.00. The company's shares closed yesterday at CHF127.30. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Telliez is an analyst with an average return of -4.3% and a 41.84% success rate. Telliez covers the Healthcare sector, focusing on stocks such as Idorsia Ltd, Genfit, and Adocia SA. In addition to Kepler Capital , Galderma Group AG also received a Buy from Jefferies's Benjamin Jackson CFA in a report issued yesterday. However, on July 16, RBC Capital maintained a Hold rating on Galderma Group AG (Six Swiss: GALD).
Business Insider
11-07-2025
- Business
- Business Insider
Kepler Capital Reaffirms Their Hold Rating on GenSight Biologics SA (G49N)
Kepler Capital analyst Justine Telliez maintained a Hold rating on GenSight Biologics SA on July 9 and set a price target of €0.40. The company's shares closed last Tuesday at €0.11. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Telliez covers the Healthcare sector, focusing on stocks such as Idorsia Ltd, Adocia SA, and Genfit. According to TipRanks, Telliez has an average return of -4.6% and a 44.90% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for GenSight Biologics SA with a €0.40 average price target. Based on GenSight Biologics SA's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €897 thousand and a GAAP net loss of €8.15 million. In comparison, last year the company earned a revenue of €248 thousand and had a GAAP net loss of €14.26 million
Business Insider
09-07-2025
- Business
- Business Insider
Kepler Capital Reaffirms Their Hold Rating on Idorsia Ltd (IDIA)
Kepler Capital analyst Justine Telliez maintained a Hold rating on Idorsia Ltd on July 7 and set a price target of CHF2.20. The company's shares closed yesterday at CHF2.24. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Telliez is an analyst with an average return of -5.8% and a 41.05% success rate. Telliez covers the Healthcare sector, focusing on stocks such as Idorsia Ltd, Ipsen, and Valneva. The word on The Street in general, suggests a Hold analyst consensus rating for Idorsia Ltd with a CHF2.20 average price target. Based on Idorsia Ltd's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of CHF58.88 million and a net profit of CHF63.12 million. In comparison, last year the company earned a revenue of CHF10.06 million and had a net profit of CHF29.86 million
Business Insider
09-07-2025
- Business
- Business Insider
Ipsen (0MH6) Receives a Hold from Kepler Capital
Kepler Capital analyst Justine Telliez maintained a Hold rating on Ipsen on July 7 and set a price target of €120.00. The company's shares closed last Monday at €103.20. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Telliez covers the Healthcare sector, focusing on stocks such as Idorsia Ltd, Ipsen, and Valneva. According to TipRanks, Telliez has an average return of -5.8% and a 41.05% success rate on recommended stocks. Currently, the analyst consensus on Ipsen is a Moderate Buy with an average price target of €121.71.
Business Insider
09-07-2025
- Business
- Business Insider
Valneva (0OB3) Gets a Buy from Kepler Capital
In a report released on July 7, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva, with a price target of €8.10. The company's shares closed yesterday at €2.43. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Telliez is an analyst with an average return of -5.8% and a 41.05% success rate. Telliez covers the Healthcare sector, focusing on stocks such as Idorsia Ltd, Ipsen, and Valneva. Valneva has an analyst consensus of Moderate Buy, with a price target consensus of €8.10.
